Together Beyond COVID-19 - A Look to the Future

International Pharmaceutical Industry: Marta Vila Ramos discusses the impact of COVID-19 on the industry and what we can expect in the future.

Posted:

Read

IPI publication: Non-clinical safety evaluation of vaccines accelerating clinical development

International Pharmaceutical Industry: Sebastian Joseph discusses regulatory expectations for the non-clinical development of vaccines

Posted:

Read

Chemistry Today publication: Non-clinical safety evaluation of vaccines accelerating clinical development

Chemistry Today: Sebastian Joseph discusses regulatory expectations for the non-clinical development of vaccines

Posted:

Read

Supporting M&As in the pharmaceutical/biopharmaceutical industry

Manufacturing Chemist: At PharmaLex, we believe we have a unique understanding of the cultural challenges experienced during M&As. Having merged ourselves in 2017 into PharmaLex, we have insight in how to overcome the challenges of maintaining agility while benefiting from working in a bigger corporate environment, having economies of scale with an increased resource pool.

Posted:

Read

Non-clinical safety evaluation of vaccines part II

Manufacturing Chemist: Sebastian Joseph discusses regulatory expectations for the non-clinical development of vaccines

Posted:

Read

Non-clinical safety evaluation of vaccines part I

Manufacturing Chemist: Sebastian Joseph discusses regulatory expectations for the non-clinical development of vaccines

Posted:

Read

Together Beyond COVID-19

PharmaLex.perts Jürgen Hönig and Lisa Pascoe discuss the challenges COVID-19 has placed on the pharma industry – from R&D to clinical trials and manufacturing to drug safety – and how companies like PharmaLex are working together with the industry to ensure regulatory compliance.

Posted:

Read

In the case of a ‘no deal’ Brexit: the supply of medicines

Jonathan Trethowan looks at how we can safeguard our supply of medicines in the case of ‘no deal’ Brexit

Posted:

Read

Brexit Uncertainty - impact on medicines supply

PharmaLex Vice President Regulatory and Scientific Policy, Jonathan Trethowan looks at what impact Brexit might have on medicines supply across the EU

Posted:

Read

The 5 things you want to know about Artificial Intelligence

PharmaLex CEO, Tilo Netzer explains the five things you should know about Artificial Intelligence

Posted:

Read

Moving From Artificial Trials To Smarter Regulatory Process

PharmaLex’s Bruno Boulanger discusses the impact big data will have on how the pharmaceutical industry gathers and delivers data in the future. *subscription required*

Posted:

Read